GT Biopharma
GTBP
31 hedge funds and large institutions have $1.11M invested in GT Biopharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
11% more funds holding
Funds holding: 28 → 31 (+3)
7.82% less ownership
Funds ownership: 16.69% → 8.87% (-7.8%)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
92% less capital inflows, than outflows
Capital inflows: $106K | Capital outflows: $1.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$48.2K |
| 2 |
Millennium Management
New York
|
+$31.6K |
| 3 |
Renaissance Technologies
New York
|
+$7.78K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.26K |
| 5 |
MCG
McCollum Christoferson Group
Amherst,
New York
|
+$5.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$1.21M |
| 2 |
BlackRock
New York
|
-$24.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20.4K |
| 4 |
Jane Street
New York
|
-$10.4K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.6K |
GTBP Hedge Fund Activity: Q2 2023 in Review
31 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2023, worth a combined $1.11M — down 64% from $3.05M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GTBP positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Bank of Montreal, adding an estimated $48.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.21M sold.
- 31 institutional investors held GT Biopharma (GTBP) as of Q2 2023, up from 28 in Q1 2023.
- Funds reported $1.11M of GT Biopharma stock for Q2 2023, down 64% quarter-over-quarter.
- 5 funds opened new GT Biopharma positions in Q2 2023 and 2 closed out, a net change of +3 holders.
- The largest GT Biopharma buyer in Q2 2023 was Bank of Montreal, an estimated $48.2K added.
- The largest GT Biopharma seller in Q2 2023 was Armistice Capital, an estimated $1.21M sold.
Based on aggregated 13F filings for Q2 2023.